HK Stock MarketDetailed Quotes

BIOSTAR PHARM-B (02563)

Watchlist
  • 3.860
  • +0.020+0.52%
Not Open Apr 8 15:53 CST
1.41BMarket Cap-9.67P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

BIOSTAR PHARM-B (02563) Revenue Breakdown Overview

By Business/Source

Currency:CNY
2025/FY
Stock NameRevenueRatio
研发、制造及销售创新药物33.36M100.00%

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
研发、制造及销售创新药物33.36M100.00%

By Country/Region

No Data

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +1.54%
Sample Name
Sample Code
 -1.88%
Sample Name
Sample Code
 -7.94%
4
SINOPEC CORP
00386
-9.58%
5
SINO OIL & GAS
00702
-12.82%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +27.77%
Sample Name
Sample Code
 +15.26%
Sample Name
Sample Code
 +7.10%
4
Hangzhou Shunwang Technology
300113
-4.89%
5
Rockchip Electronics
603893
-8.96%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -